Insmed rises on FDA priority review for lung disease drug
BUZZ-Insmed rises on FDA priority review for lung disease drug ** Shares of drugmaker Insmed INSM.O rise 2% to $122.41 premarket
** Co says US FDA grants priority review to its application seeking full approval of its drug, Arikayce, for Mycobacterium avium complex (MAC) lung disease, a rare infection that can permanently damage the lungs
** Full approval could expand the drug's use to newly diagnosed patients and those with recurring infections; it currently has accelerated approval for patients who have not responded to standard treatment
** FDA sets January 28, 2027, as target date for its decision
** Application is backed by a late-stage study in which Arikayce, when added to other medicines, improved respiratory symptoms and helped clear the infection compared with standard treatment alone
** As of last close, INSM down 31.1% YTD
(Reporting by Kunal Das in Bengaluru)
Recent news on Insmed Incorporated
See all newsBrief: Insmed Launches Brinsupri® Tablets 25 Mg (Brensocatib Hydrate) For The Treatment Of Non-Cystic Fibrosis Bronchiectasis In Japan
Brief: Insmed Incorporated - Launches Four Pivotal Phase 3 Studies For TPIP In Pulmonary Diseases
U.S. STOCKS ON THE MOVE-Nike, Synopsys, Intel
Insmed CFO Sara Bonstein steps down; shares fall
U.S. STOCKS ON THE MOVE- Cenovus Energy, TeraWulf, Alector